sTILs Warrant Research as Response Biomarker in Metastatic Breast Cancer
June 9th 2023Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.